drugset / Trial / NCT07104799
Momelotinib During and After HCT in Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Timeline
- Start
- 2026-02-23
- Primary completion
- 2028-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Momelotinib | Small molecule | 100 mg | Oral |
| Subject | Momelotinib | Small molecule | 150 mg | Oral |
| Subject | Momelotinib | Small molecule | 200 mg | Oral |